{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:46:15Z","timestamp":1786715175154,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/0973-1482.204849","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T06:04:42Z","timestamp":1492668282000},"page":"1471","source":"Crossref","is-referenced-by-count":11,"title":["Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia"],"prefix":"10.4103","volume":"15","author":[{"given":"Xianqi","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.275634-1","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","article-title":"Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies","author":"Bhalla","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-2","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1038\/sj.onc.1205598","article-title":"DNA methylation and gene silencing in cancer: Which is the guilty party?","author":"Clark","year":"2002","journal-title":"Oncogene"},{"key":"key-10.4103\/0973-1482.275634-3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2005.05590.x","article-title":"Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome","author":"Brakensiek","year":"2005","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0973-1482.275634-4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.leu.2401719","article-title":"Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes","author":"Aoki","year":"2000","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.275634-5","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275634-6","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"key-10.4103\/0973-1482.275634-7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2400526","article-title":"Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome","author":"Wijermans","year":"1997","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.275634-9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients","author":"Wijermans","year":"2000","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-10","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.275634-11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.275634-12","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cncr.22376","article-title":"Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.275634-14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.275634-15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.275634-16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1358\/dot.2007.43.6.1062666","article-title":"DNA methyltransferases as targets for cancer therapy","author":"Ghoshal","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"key-10.4103\/0973-1482.275634-17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00277-008-0583-8","article-title":"A limited number of 5-azacitidine cycles can be effective treatment in MDS","author":"M\u00fcller-Thomas","year":"2009","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.275634-18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2011.046078","article-title":"A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome","author":"Lee","year":"2011","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1482.275634-19","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the cancer and leukemia group B","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-005-0012-1","article-title":"An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients","author":"Wijermans","year":"2005","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.275634-21","first-page":"1","article-title":"Morphologic, immunologic, and cytogenetic (MIC) working classification of the primary myelodysplastic syndrome and therapy-related myelodysplasias and leukemias","author":"Third","year":"1988","journal-title":"Cancer Genet Cytogenet"},{"key":"key-10.4103\/0973-1482.275634-22","first-page":"1315","article-title":"Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases","author":"Morel","year":"1993","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.275634-23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0145-2126(99)00032-6","article-title":"Comparisons of prognostic scoring systems for myelodysplastic syndromes: A Korean multicenter study","author":"Lee","year":"1999","journal-title":"Leuk Res"},{"key":"key-10.4103\/0973-1482.275634-24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","article-title":"Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML","author":"Scandura","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.275634-25","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275634-26","doi-asserted-by":"crossref","unstructured":"Jain N, Mateusz GN, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, et a l. Benefit of Anti-infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-risk Myelodylaxis in Patients with Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Receiving Frontline \u201cTargeted Therapy\u201d. 49t h American Society of Hematology Annual Meeting. Atlanta, Georgia; 2007. p. 2858.","DOI":"10.1182\/blood.V110.11.2858.2858"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:56Z","timestamp":1786713956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0973-1482.204849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"alternative-id":["275634"],"URL":"https:\/\/doi.org\/10.4103\/0973-1482.204849","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}